Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Rc, Donehower"'
Autor:
Sd, Gore, Ek, Rowinsky, Cb, Miller, Griffin C, Tl, Chen, Borowitz M, Rc, Donehower, Kl, Burks, Dk, Armstrong, Pj, Burke, Grever MR, Scott Kaufmann
Publikováno v:
Europe PubMed Central
To further evaluate the activity of topotecan (TPT) in acute leukemia, TPT was administered (2.1 mg/m2/day for 5 days by continuous i.v. infusion) to adult patients with previously untreated acute lymphoblastic leukemia (ALL) with high-risk features
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::468edef9a375d5aee24514b70f53b866
https://pubmed.ncbi.nlm.nih.gov/9829718
https://pubmed.ncbi.nlm.nih.gov/9829718
Autor:
Lb, Grochow, Ek, Rowinsky, Johnson R, Ludeman S, Scott Kaufmann, Fl, Mccabe, Br, Smith, Hurowitz L, DeLisa A, Rc, Donehower
Publikováno v:
Europe PubMed Central
Topotecan, a semisynthetic water-soluble analog of camptothecin, is the first topoisomerase I-directed drug to enter clinical trial in the United States in over 20 yr. In this study, 30-min infusions of topotecan were administered daily for 5 days ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::55834875de21d8bcaba88a44f506ce5e
https://pubmed.ncbi.nlm.nih.gov/1358575
https://pubmed.ncbi.nlm.nih.gov/1358575
Publikováno v:
Europe PubMed Central
The effects of taxol on antitubulin immunofluorescent staining patterns, cellular DNA content, and labeling with [3H]thymidine were measured for the taxol-sensitive HL60 and taxol-resistant K562 cell lines after exposures for 0, 4, 12, and 24 h. Taxo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f174b31390ea02098d38ffbb543c3393
https://pubmed.ncbi.nlm.nih.gov/1967550
https://pubmed.ncbi.nlm.nih.gov/1967550
Publikováno v:
Blood. 73(1)
A predictable increase in the proliferative rate of malignant cells remaining after initial cytoreduction in vivo forms the rationale for timed sequential therapy (TST) with 1-B-D-arabinofuranosylcytosine (ara- C) for adult acute myelogenous leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c800745254a3e1fd6b52734554eb8d6
https://pubmed.ncbi.nlm.nih.gov/2910362
https://pubmed.ncbi.nlm.nih.gov/2910362
Autor:
Ek, Rowinsky, Scott Kaufmann, Sd, Baker, Cb, Miller, Se, Sartorius, Mk, Bowling, Tl, Chen, Rc, Donehower, Sd, Gore
Publikováno v:
Europe PubMed Central
The principal objectives of this study were to determine the feasibility of escalating doses of the hydrophilic topoisomerase I (topo I) inhibitor topotecan (TPT) as a 30-min infusion daily for 5 days in adults with refractory or relapsed acute leuke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::572c32de8076061ede5113a2df5e8323
http://europepmc.org/abstract/med/9816150
http://europepmc.org/abstract/med/9816150
Autor:
Aa, Adjei, Ii, Budihardjo, Ek, Rowinsky, Tj, Kottke, Pa, Svingen, Ca, Buckwalter, Lb, Grochow, Rc, Donehower, Scott Kaufmann
Publikováno v:
Europe PubMed Central
Pyrazoloacridine (PA), an acridine congener that has shown selective toxicity in solid tumor cells, full activity against noncycling and hypoxic cells, and promising activity in a recent Phase I trial, is currently undergoing Phase II testing as a so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f1ea332ef7c5dcc7a56fa6fb696bd103
http://europepmc.org/abstract/med/9815747
http://europepmc.org/abstract/med/9815747
Publikováno v:
Europe PubMed Central
Topotecan (TPT, 9-dimethylaminomethyl-10-hydroxycamptothecin) is the first topoisomerase I-directed cytotoxic agent to enter clinical trials in the United States in two decades. The effect of P-glycoprotein (Pgp) overexpression on TPT cytotoxicity wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4565cd1fd6b752734de5432605b14005
http://europepmc.org/abstract/med/1348448
http://europepmc.org/abstract/med/1348448
Autor:
Sena LA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Sedhom R; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.; Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Scott S; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Kagan A; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Marple AH; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Canzoniero JV; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Hsu M; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Qasim Hussaini SM; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Herati AS; Department of Urology, Johns Hopkins University, Baltimore, MD., Reschke L; Department of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, MD., Antero MF; Department of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, MD., Christianson MS; Department of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, MD., Binder AF; Department of Oncology, Thomas Jefferson University, Philadelphia, PA., Chen AR; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Donehower RC; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Marrone KA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Gupta A; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.; Division of Hematology, Oncology, Transplantation, University of Minnesota, Minneapolis, MN.
Publikováno v:
JCO oncology practice [JCO Oncol Pract] 2022 Mar; Vol. 18 (3), pp. e403-e411. Date of Electronic Publication: 2021 Sep 25.
Autor:
Bible KC; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Menefee ME; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA., Lin CJ; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Millward MJ; Department of Medical Oncology, University of Western Australia, Perth, Australia., Maples WJ; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA., Goh BC; Division of Medical Oncology, National University Cancer Institute, Singapore, Singapore., Karlin NJ; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA., Kane MA; Department of Medical Oncology, University of Colorado, Denver, Colorado, USA., Adkins DR; Division of Medical Oncology, Department of Medicine, Washington University, St. Louis, Missouri, USA., Molina JR; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Donehower RC; Division of Medical Oncology, Department of Medicine, Johns Hopkins, Baltimore, Maryland, USA., Lim WT; Division of Medical Oncology, National University Cancer Institute, Singapore, Singapore., Flynn PJ; Minnesota Oncology, Minneapolis, Minnesota, USA., Richardson RL; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Traynor AM; Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA., Rubin J; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., LoRusso PM; Department of Oncology, Wayne State University, Detroit, Michigan, USA., Smallridge RC; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA., Burton JK; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Suman VJ; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Kumar A; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Voss JS; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Rumilla KM; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Kipp BR; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Chintakuntlawar AV; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Harris P; Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland, USA., Erlichman C; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Publikováno v:
Thyroid : official journal of the American Thyroid Association [Thyroid] 2020 Sep; Vol. 30 (9), pp. 1254-1262. Date of Electronic Publication: 2020 Jul 29.
Autor:
Yarchoan M; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Huang CY; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Zhu Q; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Ferguson AK; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Durham JN; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Anders RA; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Thompson ED; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Rozich NS; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Thomas DL 2nd; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Nauroth JM; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Rodriguez C; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Osipov A; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., De Jesus-Acosta A; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Le DT; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Murphy AG; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Laheru D; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Donehower RC; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Jaffee EM; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Zheng L; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Azad NS; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publikováno v:
Cancer medicine [Cancer Med] 2020 Feb; Vol. 9 (4), pp. 1485-1494. Date of Electronic Publication: 2019 Dec 26.